title: Successful treatment with infliximab for Behçet disease during pregnancy.
abstract: OBJECTIVE
  To report a case of successful treatment with infliximab for Behçet disease (BD) during pregnancy.
  
  
  METHODS
  A case report.
  
  
  METHODS
  A 30-year-old woman was diagnosed with BD at 12 weeks of pregnancy. Additional symptoms occurred, and infliximab at a dose of 5 mg/kg body weight was initiated at 18 weeks and repeated.
  
  
  RESULTS
  All symptoms improved, and a 3950-g infant was delivered uneventfully without any abnormality at 39 weeks. A few weeks after delivery, uveitis and systemic symptoms relapsed. Infliximab was reinitiated and all symptoms were resolved.
  
  
  CONCLUSIONS
  Infliximab may be safe and effective for BD during pregnancy.
authors.forename: Kei
authors.initials: K
authors.lastname: Takayama
authors.forename: Sho
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Toshio
authors.initials: T
authors.lastname: Enoki
authors.forename: Teruo
authors.initials: T
authors.lastname: Kojima
authors.forename: Masaru
authors.initials: M
authors.lastname: Takeuchi
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007231:Infant, Newborn; D000069285:Infliximab; D011247:Pregnancy; D011248:Pregnancy Complications; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab